New oral GLP‑1 hits U.S.
Eli Lilly’s oral GLP‑1 pill Foundayo (orforglipron) is now available in the U.S., adding another non‑injectable option for people seeking medical weight loss. (prnewswire.com) That matters beyond health: analysts expect wider GLP‑1 access to reshape consumer behavior — Bernstein estimates the class could boost apparel spending by about $13 billion a year as people refresh wardrobes after weight change. ( )
A weight-loss drug used to mean a weekly shot and a refrigerator. On April 10, Eli Lilly said its new pill Foundayo, the brand name for orforglipron, is now on U.S. pharmacy shelves after the Food and Drug Administration approved it on April 1. (prnewswire.com) This is a glucagon-like peptide-1 drug, which is a medicine that copies a gut hormone your body already uses after you eat. That hormone slows stomach emptying and helps people feel full sooner, which is why these drugs can drive large weight loss over months. (ajmc.com) Foundayo is for adults with obesity, or adults who are overweight and also have at least one weight-related condition. Lilly says it is a once-daily pill that can be taken at any time of day without food or water restrictions, which separates it from earlier oral options with stricter instructions. (prnewswire.com) In Lilly’s ATTAIN-1 trial, adults on the highest dose lost an average of 27 pounds. The Food and Drug Administration said the approval came just 50 days after filing under its Commissioner’s National Priority Voucher pilot, making it the fastest approval of a new molecular entity since 2002. (prnewswire.com) (fda.gov) The timing matters because Novo Nordisk already launched an oral Wegovy pill in early 2026. CNBC reported on April 1 that Lilly’s approval arrived about three months after Novo’s pill hit the market, turning weight-loss tablets into the next front in the Lilly-Novo rivalry that already reshaped the injection market. (cnbc.com) Lilly is also using price and delivery to widen the funnel. The company said Foundayo will be available through LillyDirect with free home delivery, starting at $25 a month for commercially insured patients and $149 for self-pay patients. (prnewswire.com) Once these drugs move from injections to pills, the audience can get bigger for a simple reason: swallowing a tablet fits more easily into daily life than learning to use a pen injector. That is why analysts are watching not just drug sales, but everything people buy after their bodies change. (cnbc.com) Bernstein estimates wider glucagon-like peptide-1 use could add as much as $13 billion a year to U.S. apparel spending. Its analyst Aneesha Sherman told CNBC the likely winners include off-price chains like T.J. Maxx, mass retailers like Walmart and Target, and fit-sensitive businesses like Stitch Fix and Rent the Runway. (cnbc.com) The math is simple: if millions of people move down one or two clothing sizes, closets have to be rebuilt piece by piece. Bernstein’s estimate, as cited by CNBC and retail trade coverage, assumes shoppers replace basics, workwear, and activewear as their measurements change during treatment. (cnbc.com) (sgbonline.com) So this launch is not just another drug approval. It is the moment the weight-loss market moves one step closer to the convenience of a daily cholesterol pill, and that convenience is why retailers, insurers, and rival drugmakers are all paying attention at the same time. (fda.gov) (cnbc.com)
